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Supplementary methods

Inclusion and exclusion criteria
All participants satisfied the following criteria at study entry:
 Participants who, in the opinion of the investigator, could and would comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits);
 A male or female between, and including, 18 and 50 years of age at the time of obtaining informed consent;
 Written (or thumb printed and witnessed) informed consent obtained from the participant;
 Baseline positive interferon-gamma release assay (IGRA) test result;
 Baseline negative human immunodeficiency virus (HIV) screen;
 Baseline negative clinical screening questionnaire and negative sputum sample for pulmonary tuberculosis disease;
 Healthy participants or those with chronic well controlled disease as established by medical history and clinical examination;
 Female participants of non-childbearing potential could be enrolled in the study;
 Non-childbearing potential was defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause  Female participants of childbearing potential could be enrolled in the study, if the participant:
 had practiced adequate contraception* for 25 days prior to vaccination, and  had a negative pregnancy test on the day of screening and the day of first vaccination, and  agreed to continue adequate contraception* during the entire vaccination period and for 2 months after completion of the vaccination series.
*Adequate contraception was defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly and when applicable, in accordance with the product label for example:
 abstinence from penile-vaginal intercourse, when this was their preferred and usual lifestyle,  oral contraceptives, either combined or progestogen alone,  injectable progestogen,  implants of etonogestrel or levonorgestrel,  estrogenic vaginal ring,  percutaneous contraceptive patches,  intrauterine device or intrauterine system,  male partner sterilization prior to the female participant's entry into the study, and this male was the sole partner for that participant (the information on the male sterility could come from the site personnel's review of the subject's medical records or from interview with the participant on her medical history),  male condom combined with a vaginal spermicide (foam, gel, film, cream or suppository),  male condom combined with a female diaphragm, either with or without a vaginal spermicide (foam, gel, film, cream, or suppository).
Adequate contraception did not apply to subjects of child bearing potential with same sex partners, when this was their preferred and usual lifestyle.
The following criteria should be checked at the time of study entry. If any exclusion criterion applied, the participant could not be included in the study:
 Current tuberculosis (TB) disease or history of TB disease and/or treatment for TB (including isoniazid preventive therapy);
 Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period;
 Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after each dose of vaccine;
 History of previous administration of experimental Mycobacterium tuberculosis (Mtb) vaccines;
 Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose (for corticosteroids, this meant prednisone ≥20 mg/day or equivalent). Inhaled and topical steroids were allowed;
 Any condition or illness (acute, chronic or history) or medication, which in the opinion of the investigator could interfere with the evaluation of the safety or immunogenicity of the vaccine;
 Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required);.
 Planned participation or participation in another experimental protocol during the study;
 Concurrently participating in another clinical study, at any time during the study period, in which the participant had been or would be exposed to an investigational or a non-investigational product (pharmaceutical product or device);
 Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period;
 History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines;.
 History of medically confirmed autoimmune disease (e.g. type I diabetes, lupus);
 Pregnant or lactating female;
 Female planning to become pregnant or planning to discontinue contraceptive precautions during the vaccination period and/or before 2 months after completion of the vaccination series.
Screening procedures
The following procedures were conducted at the screening visit, -30 to 0 days before the first immunization:
 Recording of informed consent and check of inclusion/exclusion criteria;  Collection of demographic data, medical history and physical examination;  HIV testing with pre-test and post-test counselling. HIV-positive participants at screening were referred for confirmatory HIV diagnosis and management, and were not enrolled (exclusion criterion);  Documentation of history of Bacille Calmette-Guérin (BCG) vaccination/presence of scar;  Documentation of history of TB household contacts;  A urine pregnancy test was performed on all female participants of childbearing potential;  Blood sampling for QuantiFERON Gold In-Tube test;  Sputum collection for polymerase chain reaction (PCR) testing;  Reporting of serious adverse events (SAEs).
QuantiFERON TB Gold In-Tube assay
QuantiFERON-TB Gold In-Tube is an in vitro diagnostic test using peptide cocktails of ESAT-6, CFP-10 and TB7.7 proteins to stimulate cells in heparinized whole blood. These proteins are absent from all BCG strains and from most non-tuberculosis mycobacteria with the exception of M. kansarii, M. szulgai and M. marinum. The assay was performed according to the manufacturer's instructions. Briefly, blood was collected directly into QuantiFERON-TB Gold In-Tube collection tubes including a Nil Control tube, TB antigen tube and Mitogen Control tube. The tubes were incubated for 16-24 hours at 37°C prior to harvesting plasma. Interferon (IFN)- concentrations in plasma were determined using the QuantiFERON-TB Gold enzyme-linked immunosorbent assay (ELISA) kit (manufacturer recommended cut-off 0.35 IU/ml).
No IGRA test was performed beyond baseline. The authors acknowledge this limitation and agree that some participants might have reverted to negative IGRA during the study. IGRA reversion has not been definitively shown to be associated with decreased risk of progression to TB disease. 1 The impact on the final analysis could be a diluted effect on overall TB incidence associated with IGRA reversion, which would not be expected to differentially affect TB disease incidence by study arm. It is also interesting to note that the attack rate in our study was in line with the expectations and therefore, the rate of IGRA reversion may be assumed to be limited.
Composition of vaccine and placebo
0.5 ml dose of M72/AS01 E contains 10g M72 reconstituted with AS01E, a GSK proprietary Adjuvant System which contains 25 g MPL (3-O-desacyl-4-monophosphoryl lipid A produced by GSK), 25 g QS-21 (Quillaja saponaria Molina, fraction 21; licensed by GSK from Antigenics Inc., a wholly owned subsidiary of Agenus Inc., a Delaware, USA corporation), and liposomes.
The placebo consisted of sucrose 20 mg/dose in phosphate buffer pellet that was reconstituted with -Tocopherol, squalene and Tween 80. Each dose was administered intramuscularly in the deltoid region of the arm.
Treatment allocation and randomization
Samples were randomized in blocks at GSK Biological, using MATerial EXcellence.
Participants were allocated to a study group at the investigator site using an internet based randomization system. The randomization algorithm used a minimization procedure accounting for center and gender. Minimization factors had equal weight in the minimization algorithm. A random element was included in the algorithm to avoid fully deterministic allocations.
Safety monitoring plan
Planned safety review by the Safety Review Team and the Independent Data Monitoring Committee (IDMC)
A planned safety review occurred after the first 100 participants were enrolled and vaccinated. The Safety Review Team reviewed blinded safety summaries data and the IDMC reviewed the unblinded safety data, during the course of the study.
The study was conducted in a double-blind fashion and the study team and participants did not have access to unblinded individual data. Only the results per group were unblinded to the study team. In limited instances, the group can be deduced for specific participants when crossing information from different table cells, but it was considered that this does not impact the integrity of the study.
Only an external and independent statistician had access to the randomization code and generated the final analysis as well as the safety analyses for the IDMC. The IDMC members had access to the unblinded safety information 10 times during the study conduct.
Rules for vaccination
At the individual participant level,  No second dose was to be administered in a given participant who experienced Grade 3 redness and swelling, i.e. 100 mm, post-dose 1, or Grade 2 or 3 respiratory adverse events post-dose 1;
 No second dose was to be administered in a given participant who developed TB disease after dose 1.
At the study level,  An ad hoc IDMC review was to be called if 2 or more participants experienced related Grade 2 or higher respiratory adverse events within 90 days after any dose;
 Further enrollment and vaccination was to be suspended if within 90 days after any study vaccine dose any of the following events were observed:
 Any related respiratory adverse event with fatal outcome,  Two or more participants experiencing Grade 3 related respiratory adverse events.
 Vaccination could only resume pending final GSK Vaccine Safety Monitoring Board approval.
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Reporting periods for adverse events, serious adverse events and pregnancies 
Surveillance for pulmonary TB
Surveillance for efficacy commenced with administration of the first dose of study vaccine or placebo.
Active follow-up for safety and efficacy
In addition to scheduled study visits at the study facilities, regular contacts (every two months) with the study participants was maintained using one or more of the following methods:
 Regular interval home visits by site staff;
 Phone calls to inquire about current health status, completed by home visits if the participant could not be reached;
 1-way short message service (SMS) reminders and/or 2-way SMS exchange.
During study visits and contacts, participants were asked if they had signs or symptoms of pulmonary TB. Based on clinical suspicion of TB, and guided by the World Health Organization (WHO) signs and symptoms algorithm [WHO, 2009] , they were requested to provide 3 sputum samples, preferably taken in the morning and within 1 week, for testing for Mtb by PCR and liquid culture by Mycobacterial Growth Indicator Tube.
Passive follow-up for efficacy
Participants were informed about signs and symptoms compatible with TB at the time of informed consent and at each visit/contact. At any time during the study, if any participant suspected that he/she had signs and symptoms of TB, he/she was requested to self-report to the study center for clinical evaluation (passive follow-up). Confirmatory testing using PCR and microbiological culture was performed when indicated.
Diagnostic procedures for the detection of suspected pulmonary TB
Participants with clinical suspicion of pulmonary TB provided three respiratory sputum samples, preferably taken in the morning over a week, for testing by PCR and microbiological culture, for a total of six opportunities (tests) to provide evidence of microbiologically-positive TB disease. Participants with negative results but with continuing clinical suspicion of TB disease were treated with non-anti-tuberculosis antibiotics and followed up approximately 2 weeks later. If clinical suspicion persisted, 3 additional sputum samples, preferably taken in the morning and within a 1-week interval, were collected for additional PCR testing and microbiological culture. If TB disease could not be confirmed with PCR and/or microbiological culture, the participant could be given TB treatment based on other diagnostic tests (e.g. smear microscopy) and the judgement of the physician providing care.
Sputum samples were preferably to be collected before initiation of TB treatment. However, samples for diagnostic testing with PCR and/or microbiological culture could be collected up to 4 weeks after initiation of TB treatment. Definite Pulmonary TB cases identified from sputum samples taken after initiation of TB treatment were not included in the primary endpoint.
All patients with confirmed TB underwent screening for diabetes (HbA1c >6.5%) and for HIV-infection. For HIV-positive patients, additional testing measured CD4+ cell counts.
Diagnostic procedures for the detection of suspected extra-pulmonary TB
Participants with clinical suspicion of extra-pulmonary TB underwent a diagnostic procedure according to local clinical practice and as a minimum, the most recent WHO recommendations in the "International Standards for TB care".
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PCR (Xpert MTB/RIF) for Mtb detection
The PCR (Xpert MTB/RIF) assay and the GeneXpert instrument consists of a single-use multi-chambered plastic cartridge preloaded with liquid buffers and lyophilized reagent beads necessary for sample processing, DNA extraction, and hemi-nested real-time PCR. Clinical sputum samples were treated with a NaOH and isopropanol-containing sample reagent (SR). The SR was added at a 2:1 ratio to the sputum sample or sputum pellet and incubated for 15 min at room temperature. The treated sample was transferred into the cartridge, the cartridge was loaded into the GeneXpert instrument and an automatic process completes the remaining assay steps. The assay cartridge also contained lyophilized Bacillus globigii spores which serve as an internal sample processing and PCR control. The spores are automatically resuspended and processed during the sample processing step, and the resulting B. globigii DNA is amplified during the PCR step.
The standard user interface indicates the presence or absence of M. tuberculosis, the presence or absence of rifampicin (RIF) resistance, and a semi-quantitative estimate of M. tuberculosis concentration (high, medium, low, and very low). Assays that are negative for M. tuberculosis and also negative for the B. globigii internal control are reported as invalid. The PCR assay amplifies a 192-bp segment of the M. tuberculosis rpoB gene in a heminested real-time PCR. The internal control heminested B. globigii assay is multiplexed with the M. tuberculosis assay. M. tuberculosis is detected using five overlapping molecular beacon probes (probes A to E) that are complementary to the entire 81-bp RIF resistance-determining "core" region of the wild-type rpoB gene (5, 7, 14) . Mutations in the rpoB gene target inhibit hybridization of 1 or more of the rpoBspecific molecular beacons, reducing or eliminating the signal from the corresponding probes. M. tuberculosis is identified when at least 2 of the 5 rpoB-specific molecular beacons give a positive signal with cycle threshold (CT) values that are ≤38 and that differ by no more than 2 cycles. B. globigii DNA is detected when the single B. globigii molecular beacon produces a CT of <38 cycles (adapted from: Blakemore et al., 2010). 
Statistical analysis of vaccine efficacy
The primary analysis of efficacy used the according-to-protocol (ATP) cohort. Vaccine efficacy (VE) was estimated from a Cox proportional hazard regression model (VE=1-hazard ratio) and 90% confidence intervals (90% CIs) and Wald p-values were derived. 95% CIs were also defined as a post-hoc analysis. The primary analysis was unadjusted but secondary analyses evaluated the effect of potential covariates.
At final efficacy analysis, the success criterion for the primary objective was the following:
 The lower limit of the 2-sided 90% CI for VE (using a Cox regression model) against first occurrence of definite pulmonary TB disease not associated with HIV-infection, meeting the first case definition, is above 0%.
If the primary objective was met, the confirmatory secondary objective was evaluated with the following success criterion:
 The lower limit of the 2-sided 90% CI for VE (using a Cox regression model) against first occurrence of definite pulmonary TB disease not associated with HIV-infection, meeting the second case definition, is above 0%.
For all VE objectives, Kaplan-Meier survival curves were plotted and compared with the control group by means of p-values from the log rank test. VE was estimated using Cox regression.
15 1 case that remains blinded BCG = Bacille Calmette-Guérin, N = number of participants, n = number of participants in a given category, Value = value of the considered parameter, % = n / Number of participants with available results x 100, SD = standard deviation, BMI = body mass index, IQR = interquartile range * 'Other' includes 1 Indian, 449 colored and 448 mixed race individuals across both groups ** Recently exposed to a household contact diagnosed and/or treated for pulmonary tuberculosis # n varies because one case remains blinded At least one symptom = at least one symptom experienced (regardless of the MedDRA Preferred Term) N = number of participants with at least one administered dose n/% = number/percentage of participants reporting the symptom at least once 95% CI = exact 95% confidence interval; LL = lower limit, UL = upper limit For each dose and overall/participant: N = number of participants with at least one documented dose n/% = number/percentage of participants reporting the symptom at least once 95% CI = exact 95% confidence interval; LL = lower limit, UL = upper limit Grade 3 or 'severe' symptoms were defined as pain that was significant at rest and prevented normal everyday activities; redness and swelling 100 mm, temperature >39.5C, and as preventing normal activity for all other symptoms. GMC = geometric mean antibody concentration. All participants with a value below the assay cut-off are assigned a value of half the cutoff for the purposes of GMC calculation.
All (100%) M72/AS01 E recipients were seropositive for anti-M72 IgG antibodies one month post-dose 2 compared to 9.1% prior to vaccination. Compared to pre-vaccination levels, anti-M72 antibody GMCs increased by 340-fold after dose 2, and remained 26-fold higher than pre-vaccination levels at month 12. No change in the antibody response was observed in placebo recipients. 
